C12N 2770/32622
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2770/32622 (New viral proteins or individual genes, new structural or functional aspects of) appears on 65 US grants and 29 published applications in this corpus.
Search patents in C12N- Granted patents
- 65
- Published applications
- 29
- Assignees
- 29
- Inventors
- 119
- Latest grant
- 4 Jan 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 6 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 13 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 3 |
| 2003 | 2 | 5 |
| 2004 | 1 | 3 |
| 2005 | 3 | 1 |
| 2006 | 1 | 2 |
| 2007 | 3 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 3 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 1 | 3 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of cancer using recall antigens delivered by attenuated bacteria4 Jan 2022US 11,213,577 B2Albert Einstein College of Medicine
- N-antigenic form poliovirus virus-like particles comprising thermostable mutations13 Jul 2021US 11,058,760 B2University of Florida Research Foundation, Inc.
- Drug transporter permeating blood-brain barrier, peptide and use thereof13 Oct 2015US 9,156,889 B2Microbial Chemistry Research Foundation
- Chimeric lyssavirus nucleic acids and polypeptides12 Jan 2010US 7,645,455 B2Institut Pasteur
- Viral vectors useful in induction of humoral or cellular immunity24 Jul 2007US 7,247,619 B2
- Pentameric toxin protein-based target protein fusion pentamer producing platform using viral nucleocapsid2 Jul 2026US 2026/0184745 A1University-Industry Foundation, Yonsei University
- Systems and methods for protein expression23 Feb 2023US 2023/0056404 A1
- Newcastle disease virus-based vectored vaccine22 Dec 2022US 2022/0402975 A1
- Systems and methods for protein expression29 Sep 2022US 2022/0307037 A1Excepgen Inc.
- Treatment of cancer using recall antigens delivered by attenuated bacteria28 Apr 2022US 2022/0125901 A1Albert Einstein College of Medicine
Most cited
By later US patents
- Viruses with recombinant surface proteins96US 4,593,002 AThe Salk Institute Biotechnology/Industrial Associates, Inc. · 1986
- Production of complementary DNA representing RNA viral sequences by recombinant DNA methods and uses therefor36US 4,719,177 AMassachusetts Institute of Technology · 1988
- Replication-competent recombinant viral vaccines and method of producing same34US 5,965,124 AAmerican Cynamid Company · 1999
- Antigen/antibody specificity exchanger29US 6,469,143 B2Tripep AB · 2002
- Self-assembled, defective, non-self-propagating lentivirus particles27US 5,614,404 ATheriod Biologics, Incorporated · 1997